While there are still far more questions than answers about long COVID-19, researchers are beginning to get a clearer picture of the health and economic consequences of the condition.
Academic rigor, journalistic flair
Articles on Paxlovid
Displaying all articles
Analysis of Victoria’s winter COVID wave found Paxlovid and Lagevrio reduced the risk of hospitalisation and death. The results were better for Paxlovid, but not everyone can take it.
Rapid tests can be an incredibly useful tool for early detection of COVID-19. Unfortunately, they sometimes leave people with more questions than answers.
After taking Paxlovid for COVID and appearing to recover, some people – including US President Joe Biden – continue to test positive. What’s going on?
We hear a lot about drug-resistant bacteria. The same thing can happen with viruses.
According to a letter from Biden’s doctor, the president has a runny nose, mild fatigue and a slight cough. The letter also noted that Biden began taking an antiviral drug the morning he tested positive.
Here’s who is eligible, the benefits and side effects to consider.
The effects of COVID and a new treatment for it are leaving a bad taste in the mouth for many. How do we detect what’s salty, sweet, bitter, sour or umami?
An infectious disease doctor discusses the use, benefits and availability of a drug to prevent severe COVID-19.
New ethical issues are emerging during COVID-19 as doctors struggle with their obligations to ‘do no harm’ and respect patient autonomy.
Just as access to vaccines was vastly more difficult for low-income countries, the same is now true for the virus’ treatments: at potentially great cost to the world.
Both companies say their drugs will work against the Omicron variant, though this is based on preliminary, lab-based research.
Top contributors
-
Assistant Professor of Infectious Diseases, University of Virginia
-
Associate Professor in Public Health, La Trobe University
-
Director, Evidence and Methods, National COVID-19 Clinical Evidence Taskforce; Associate Professor (Research), Cochrane Australia, School of Population Health and Preventive Medicine, Monash University, Monash University
-
Director, WHO Collaborating Centre for Viral Hepatitis, The Peter Doherty Institute for Infection and Immunity
-
Associate Professor of the Sydney Pharmacy School, University of Sydney
-
Senior Technical Advisor - HIV, The Nossal Institute for Global Health, PhD candidate La Trobe University, The University of Melbourne
-
Deputy Program Director, Health Security and Pandemic Preparedness, Burnet Institute
-
Associate Professor of Viral Oncology, University of Leeds
-
Adjunct Clinical Professor, Monash University
-
Professor of general practice, Bond University
-
Pharmacist and PhD Candidate, University of Sydney
-
Research Leader in Virology and Infectious Disease, Griffith University
-
Monash University
-
Assistant Professor of Molecular Medicine, UMass Chan Medical School
-
Head of Pharmacology, Associate Professor in Pharmacology, University of Sydney
